{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:37:25Z","timestamp":1777923445912,"version":"3.51.4"},"reference-count":43,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Metabolic Syndrome and Related Disorders"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>A potentially atherogenic lipid profile often found in patients with type 2 diabetes mellitus (T2DM) includes increased concentrations of small, low-density lipoprotein (LDL) and intermediate-density lipoprotein (IDL) and decreased concentration of medium\/large high-density lipoprotein (HDL) particles. Extended-release niacin\/laropiprant (ERN\/LRPT) lowers LDL-cholesterol (LDL-C) and triglycerides (TG), and raises HDL cholesterol (HDL-C) levels with attenuation of niacin-induced flushing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Plasma HDL, LDL, IDL, very-low-density lipoprotein (VLDL), and chylomicron particle concentration and size at were evaluated at baseline and week 12 using nuclear magnetic resonance (NMR). The data were acquired from a randomized, multicenter, double-blind, placebo-controlled study including 796 patients with T2DM treated with either 1 tablet of ERN 1 gram\/LRPT 20\u2009mg or matching placebo daily, increased after 4 weeks to 2 tablets daily.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      ERN\/LRPT significantly (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u22640.001 for all) reduced LDL-C 17.9% and TG 23.1%, and increased HDL-C levels 23.2%. Compared to placebo, ERN\/LRPT decreased LDL, IDL, VLDL, and chylomicron particle concentrations [median concentration of smallest LDL particles decreased 16.6%, 95% confidence interval (CI) \u221222.3, \u221210.9, whereas the largest LDL particles decreased 11.0%, 95% CI \u221218.7, \u22123.2, and total VLDL\/chylomicron mean plasma particle concentration decreased 34.7%, 95% CI \u221241.3, \u221228.1]. Compared to placebo, ERN\/LRPT shifted the distribution of HDL particle diameter from smaller to larger (median concentration of the largest HDL particles increased 32.7% (95% CI 25.30, 40.58), whereas concentration of the smallest HDL particles decreased 8.2% (95% CI \u221211.29, \u22125.06).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Compared with placebo in patients with T2DM, ERN\/LRPT shifted the lipoprotein profile toward a potentially less atherogenic pattern with reduced atherogenic LDL and IDL particle concentrations, and increased large HDL plasma particle concentrations. (ClinicalTrials.gov: NCT00485758)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/met.2012.0005","type":"journal-article","created":{"date-parts":[[2012,3,8]],"date-time":"2012-03-08T11:21:11Z","timestamp":1331205671000},"page":"260-266","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Extended-Release Niacin\/Laropiprant Effects on Lipoprotein Subfractions in Patients with Type 2 Diabetes Mellitus"],"prefix":"10.1177","volume":"10","author":[{"given":"Harold","family":"Bays","sequence":"first","affiliation":[{"name":"L-Marc"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"Giezek","sequence":"additional","affiliation":[{"name":"MSD Europe","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"McKenney","sequence":"additional","affiliation":[{"name":"National Clinic Research"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"O'Neill","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme Corp."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Tershakovec","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme Corp."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2012,8,1]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.2007.S68"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.16.2.469"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/db09-1114"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.130301"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.106.25.3143"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000133317.49796.0E"},{"key":"e_1_3_2_8_2","first-page":"921","article-title":"Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the 2003 update","volume":"169","author":"Genest J","year":"2003","unstructured":"Genest J, , Frohlich J, , Fodor G et al. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the 2003 update. CMAJ, 2003; 169:921\u2013924.","journal-title":"CMAJ"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.1.160"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.8.1177"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(03)00394-1"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)01639-3"},{"key":"e_1_3_2_13_2","first-page":"229","article-title":"Increasing HDL cholesterol with extended-release nicotinic acid: From promise to practice","volume":"62","author":"Birjmohun RS","year":"2004","unstructured":"Birjmohun RS, , Hutten BA, , Kastelein JJ et al. Increasing HDL cholesterol with extended-release nicotinic acid: From promise to practice. Neth J Med, 2004; 62:229\u2013234.","journal-title":"Neth J Med"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1994.00420140051007"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802083408"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(85)90092-7"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-3-4"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0601574103"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm0603668"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.10.023"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-000-0096-y"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.11.018"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.14.1568"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.10.1263"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01938.x"},{"key":"e_1_3_2_26_2","first-page":"37","article-title":"Efficacy and safety of extended-release niacin\/laropiprant in patients with type 2 diabetes mellitus","volume":"18","author":"MacLean A","year":"2011","unstructured":"MacLean A, , McKenney JM, , Scott R et al. Efficacy and safety of extended-release niacin\/laropiprant in patients with type 2 diabetes mellitus. Br J Cardiol, 2011; 18:37\u201345.","journal-title":"Br J Cardiol"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/38.9.1632"},{"key":"e_1_3_2_28_2","first-page":"609","volume-title":"Handbook of Lipoprotein Testing","author":"Otvos JD","year":"2000","unstructured":"Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Rifai N, , Warnick G, , Dominiczak MH. Handbook of Lipoprotein Testing. Washington, DC: AACC Press, 2000; 609\u2013923."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2006.07.006"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.2741\/1077"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1053\/meta.2002.34701"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1988.03410130125037"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.191305"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0b013e3283325083"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011090"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199011083231901"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03450060069031"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(86)80293-5"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.08.070"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.09.013"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1987.03390230069027"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107579"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1112346"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2011.10.017"}],"container-title":["Metabolic Syndrome and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/met.2012.0005","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/met.2012.0005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/met.2012.0005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:47:16Z","timestamp":1777668436000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/met.2012.0005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1089\/met.2012.0005"],"URL":"https:\/\/doi.org\/10.1089\/met.2012.0005","relation":{},"ISSN":["1540-4196","1557-8518"],"issn-type":[{"value":"1540-4196","type":"print"},{"value":"1557-8518","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}